logo

Biomarin Pharmaceutical Inc. (BMRN)



Trade BMRN now with
  Date
  Headline
4/27/2022 4:18:39 PM BioMarin Q1 EPS $0.63 Vs. $0.09 Year Ago
3/17/2022 8:33:39 AM BioMarin Pharma Publishes Results From Phase 3 GENEr8-1 Study In Adults With Severe Hemophilia A
2/24/2022 5:37:33 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) FY22 Rev. Estimate To 2.20 Billion From 2.21 Billion
2/24/2022 5:37:15 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q4 22 Rev. Estimate To 577.7 M From 587.8 M
2/24/2022 5:37:00 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q3 22 Rev. Estimate To 559.5 M From 564.0 M
2/24/2022 5:36:47 PM Wedbush Is Raising Biomarin Pharmaceutical Inc. (BMRN) Q2 22 Rev. Estimate To 543.2 M From 540.1 M
2/24/2022 5:36:34 PM Wedbush Is Increasing Biomarin Pharmaceutical Inc. (BMRN) Q1 22 Rev. Estimate To 522.8 M From 514.9 M
2/24/2022 5:36:07 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) FY22 Estimate To 0.64 From 1.27
2/24/2022 5:35:54 PM Wedbush Is Cutting Biomarin Pharmaceutical Inc. (BMRN) Q4 22 Estimate To 0.27 From 0.54
2/24/2022 5:35:41 PM Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q3 22 Estimate To 0.23 From 0.44
2/24/2022 5:35:30 PM Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q2 22 Estimate To 0.08 From 0.17
2/24/2022 5:35:18 PM Wedbush Is Lowering Biomarin Pharmaceutical Inc. (BMRN) Q1 22 Estimate To 0.05 From 0.11
2/24/2022 5:34:50 PM Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $155 Price Target
2/23/2022 4:28:12 PM BioMarin Reports Q4 Loss Per Share $0.32 Vs. EPS Of $0.12 Last Year